GH Research (NASDAQ:GHRS) Stock Price Down 0.9% – Here’s Why

Shares of GH Research PLC (NASDAQ:GHRS) fell 0.9% during mid-day trading on Thursday . The stock traded as low as $8.64 and last traded at $8.64. 12,976 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 79,088 shares. The stock had previously closed at $8.72.

Wall Street Analysts Forecast Growth

GHRS has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reiterated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Stock Down 0.1 %

The business’s fifty day moving average is $7.76 and its 200-day moving average is $10.43.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. As a group, analysts expect that GH Research PLC will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP lifted its position in GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,310,563 shares of the company’s stock after purchasing an additional 1,471,946 shares during the period. GH Research comprises 9.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 6th largest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 at the end of the most recent reporting period. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).